Tesamorelin ���景与作用机制 — Practical Notes

By Editorial Desk · published 2026-01-22 · last reviewed 2026-03-04 · Guide

Everything below concerns hexenoyl group. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.

tesamorelin 背景与作用机制

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

Molecular Background and Receptor Mechanism

Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.

Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.

Tesamorelin at a glance

Background and Clinical Profile

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Related pages on this site

• Practical dataset
• Verified reference
• Optimized guide
• Practical playbook
• Professional casebook
• Gradual dataset
• Automated index
• Comprehensive primer

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Reference notes

January 23: Law granting an additional benefit to pregnant women already receiving allowances under the law of August 5, 1914. June 18: Law amending the law of April 7, 1915, authorizing the government to revoke naturalization decrees of former nationals of enemy countries: naturalized persons from a country at war with France can be stripped of French nationality, and this loss may extend to the wife and children depending on circumstances. July 27: Law establishing "Wards of the Nation"; women may hold positions in national and departmental offices. August 5: Law concerning breastfeeding in industrial and commercial establishments. October 1: Law on the repression of public drunkenness and regulation of drinking establishments; part of a campaign against clandestine prostitution by both women and men. Additionally, girls under 18 may no longer work in drinking establishments unless they are family members of the owner. 1919

=== Cardiac muscle === Cardiac muscle lies between the epicardium and the endocardium in the heart. Cardiac muscle cells generally only contain one nucleus, located in the central region. They contain many mitochondria and myoglobin. Unlike skeletal muscle, cardiac muscle cells are unicellular. These cells are connected to each other by intercalated disks, which contain gap junctions and desmosomes.

== Treatment == NMS is a medical emergency and can lead to death if untreated. The first step is to stop the culprit medication and treat the hyperthermia aggressively, such as with cooling blankets or ice packs to the axillae and groin. Acetaminophen is commonly used as an anti-pyretic. Supportive care in an intensive care unit capable of circulatory and ventilatory support is crucial. In those unable to control their secretions, or who have muscle spams of the respiratory muscles, mechanical ventilation may be needed. The best pharmacological treatment is still unclear. Dantrolene has been used when needed to reduce muscle rigidity, and dopamine pathway medications such as bromocriptine have shown benefit. Dantrolene may act centrally on thermoregulatory pathways to lower the temperature. Dantrolene also inhibits calcium release from the muscle sarcoplasmic reticulum to cause muscle relaxation. Amantadine is another treatment option due to its dopaminergic and anticholinergic effects. Apomorphine may be used however its use is supported by little evidence. Benzodiazepines may be used to control agitation. Highly elevated blood myoglobin levels from muscle breakdown (rhabdomyolysis) can result in kidney damage, therefore aggressive intravenous hydration with diuresis may be required. When recognized early NMS can be successfully managed; however, up to 10% of cases can be fatal. Should the affected person subsequently require an antipsychotic, trialing a low dose of a low-potency atypical antipsychotic is recommended.

==== Albums ==== Butterfly Love (Boner Records, 1989) Lurch (Boner Records, 1990) Tulip (Boner Records, 1990) The Miracle of Sound in Motion (Boner Records, 1993) Your Choice Live Series 019 (Your Choice Records, 1993) Best of Steel Pole Bathtub (Sento, 1993) Scars from Falling Down (Slash/London, 1995) Unlistenable (Zero to One, 2002)

=== Competitive and ecological roles === Beyond these interactions, Xanthoria parietina often overgrows other epilithic lichens without affecting their photobionts. It also supports microbial communities beneath its thallus, likely benefiting from microhabitats created by its attachment structures. In addition, Xanthoria parietina plays a role in biogeochemical cycling by promoting rock weathering through hyphal penetration and adhesion. Its interactions with minerals such as quartz, feldspar, and muscovite contribute to mineral breakdown, particularly in carbonate-rich substrates. Finally, the lichen competes with other foliose lichens. In experimental settings, it showed competitive equivalence with Parmelia caperata but was overgrown by Parmelia saxatilis under some conditions. In three-species mixtures, however, X. parietina often gained a competitive advantage—possibly due to its tolerance for elevated nitrogen levels. Its ability to thrive in nutrient-rich environments may allow it to outcompete acidophytic species in habitats influenced by agricultural or atmospheric nitrogen inputs. When competing with other lichens, X. parietina typically forms codominant relationships rather than completely displacing other species, particularly in early colonization stages. Field studies show that when X. parietina thalli border upon other lichens such as Physcia species, neither distinctly overgrows the other, but rather their marginal lobes intermingle. The frequent co-occurrence of X. parietina with grey-colored Physcia species may represent more than simple cohabitation.

Sources: en.wikipedia.org

Reference notes

=== Maximum-likelihood methods === The maximum-likelihood approach uses probability theory to complete all three steps simultaneously. It estimates critical parameters, including the divergence between sequences and the transition/transversion ratio, by deducing the most likely values to produce the input data.

== External links == 5 ways the heaviest element on the periodic table is really bizarre, ScienceNews.org Element 118: Experiments on discovery, archive of discoverers' official web page Element 118, Heaviest Ever, Reported for 1,000th of a Second, The New York Times. It's Elemental: Oganesson Archived 27 December 2018 at the Wayback Machine Oganesson at The Periodic Table of Videos (University of Nottingham) On the Claims for Discovery of Elements 110, 111, 112, 114, 116, and 118 (IUPAC Technical Report) WebElements: Oganesson

2003: Researchers engineer an artemisinin precursor pathway in E. coli. 2004: First international conference for synthetic biology, Synthetic Biology 1.0 (SB1.0) is held at MIT. 2005: Researchers develop a light-sensing circuit in E. coli. Another group designs circuits capable of multicellular pattern formation. 2006: Researchers engineer a synthetic circuit that promotes bacterial invasion of tumour cells. 2010: Researchers publish in Science the first synthetic bacterial genome, called M. mycoides JCVI-syn1.0. The genome is made from chemically-synthesized DNA using yeast recombination. 2011: Functional synthetic chromosome arms are engineered in yeast. 2012: Charpentier and Doudna labs publish in Science the programming of CRISPR-Cas9 bacterial immunity for targeting DNA cleavage. This technology greatly simplified and expanded eukaryotic gene editing. 2019: Scientists at ETH Zurich report the creation of the first bacterial genome, named Caulobacter ethensis-2.0, made entirely by a computer, although a related viable form of C. ethensis-2.0 does not yet exist. 2019: Researchers report the production of a new synthetic (possibly artificial) form of viable life, a variant of the bacteria Escherichia coli, by reducing the natural number of 64 codons in the bacterial genome to 59 codons instead, in order to encode 20 amino acids. 2020: Scientists created the first xenobot, a programmable synthetic organism derived from frog cells and designed by AI. Demis Hassabis and John M. Jumper presented an AI model called AlphaFold2.

and Eyad A., accused of committing war crimes in Syria's government-run detention center, appeared in a German court for a first of its kind trial. According to a 2018 report released by the expert panel of United Nations, the Assad government-run detention centers tortured more than 4,000 of the detained protestors and murdered at least 58 others.

Sources: en.wikipedia.org

Frequently asked questions